Novel Diabetes Treatment

Back to all technologies
Download as PDF
2013-GHOS-66610
Diabetes is a widely prevalent disease that currently affects 25.8 million people in the United States. The predominant form of diabetes is characterized by hyperglycemia resulting from a combination of reduction in pancreatic beta cell activity and mass, which leads to insufficient insulin production. An enzyme called memapsin 1 is known to be part of the biochemical pathway that leads to the problems with pancreatic beta cells and ultimately causes insulin deficiency. Memapsin 1 deactivates a transmembrane protein shown to increase beta cell proliferation and improve glucose stimulated insulin secretion. The transmembrane protein is deactivated when it undergoes ectodomain cleavage in a process triggered by memapsin 1.

Researchers at Purdue University in collaboration with Oklahoma Medical Research Foundation have developed and assayed a series of lead compounds that act as memapsin 1 inhibitors and increase pancreatic beta cell mass. Treatment with these compounds may also be complimented by other therapeutics that increase insulin production, improve glucose homeostasis, or inhibit hyperglucagonemia.

Advantages:
-Improved glucose homeostasis
-Specific enzyme pathway regulation

Potential Applications:
-Medical/Healthcare
-Pharmaceuticals
Sep 12, 2014
Utility Patent
United States
9,512,099
Dec 6, 2016

Mar 11, 2013
Utility Patent
United States
9,096,541
Aug 4, 2015

Sep 13, 2013
Provisional-Patent
United States
(None)
(None)

Mar 11, 2013
PCT-Patent
WO
(None)
(None)

Mar 29, 2012
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org